Intrinsic Bioprobes Receives US Patent for Protein Biomarkers for Myocardial Infarction
October 29, 2010
Intrinsic Bioprobes Receives US Patent for Protein Biomarkers for Myocardial Infarction
According to the patent, the company identified the proteins serum amyloid A and S-sulfonated transthyretin as biomarkers for myocardial infarction and developed a three-marker panel consisting of SAA, SS-TTR, and known MI biomarker myoglobin.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- 26,000-Patient Study Suggests Triple-Biomarker Approach Could Improve CKD Diagnosis
April 29, 2011 / ProteoMonitor - Thermo Fisher and IBI Team Up to Bring MSIA Technology Into the Clinic
July 16, 2010 / ProteoMonitor - Biodesign Institute, Pfizer Collaborating on $5M Diabetes Protein Biomarker Project
November 4, 2011 / ProteoMonitor - Thermo Fisher Acquires Proteomics Firm Intrinsic Bioprobes
September 2, 2011 / ProteoMonitor - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor